SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Rights Issue 2023
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
Press Releases
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
10/2/2023
Anders Essen-Möller has been appointed Chairman of the Board of Diamyd Medical
9/20/2023
The Board of Directors in Diamyd Medical resolves on a rights issue of approximately SEK 243 million
9/5/2023
Registrational Phase III trial in Type 1 Diabetes with Diamyd
®
expands to the US
8/16/2023
Results from Diamyd
®
Antigen-Specific Immunotherapy Trial in LADA published in scientific journal
6/28/2023
Diamyd Medical announces final outcome in the company’s rights issue
6/28/2023
Quarterly Report III 22/23
6/27/2023
Diamyd Medical announces preliminary outcome in the company’s rights issue
6/26/2023
Bulletin from Extra General Meeting of Diamyd Medical AB
6/19/2023
Diamyd Medical's largest owner fully subscribes for his share in the ongoing rights issue
6/13/2023
Diamyd Medical refrains from enforcing the underwriting agreements in the rights issue and extends the subscription period
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research